Online Exclusive Article

Effect of Kefir on the Quality of Life of Patients Being Treated for Colorectal Cancer

Gulbeyaz Can

Erkan Topuz

Duygu Derin

Zehra Durna

Adnan Aydiner

complementary and alternative therapies, colorectal cancer
ONF 2009, 36(6), E335-E342. DOI: 10.1188/09.ONF.E335-E342

Purpose/Objectives: To determine kefir's effect on the prevention of gastrointestinal complaints and quality of life (QOL) in patients being treated for colorectal cancer.

Design: Randomized, controlled, prospective, interventional study.

Setting: Istanbul University Oncology Institute in Turkey.

Sample: 40 patients, 20 of whom were randomized to the experimental (kefir) arm and 20 who were randomized to the control arm.

Methods: Informed consent to participate in the study was obtained. Before treatment began, demographics, illness-related characteristics, complaints, and QOL of participants were evaluated. During treatment, side effects were evaluated one week after every cycle of therapy. QOL was evaluated after the third and sixth cycles of treatment.

Main Research Variables: The effect of kefir on the prevention of gastrointestinal complaints and QOL in patients being treated for colorectal cancer.

Findings: Following chemotherapy, the experimental (kefir) group had more treatment-related gastrointestinal complaints but a decrease in sleep disturbance. No difference was found between the two groups for QOL.

Conclusions: Kefir does not prevent or decrease gastrointestinal complaints in patients undergoing chemotherapy for colorectal cancer. Kefir did decrease sleep disturbances in the experimental group.

Implications for Nursing: Many patients use complementary and alternative medicine during cancer therapy. This study may provide information about the effectiveness of kefir in patients with cancer.

Jump to a section

    References

    Aydıner, A., & Topuz, E. (2004). Antalya consensus on breast cancer, gastrointestinal cancers, and lung cancers—Diagnosis, treatment, follow up. Istanbul, Turkey: Nobel Medical Books.
    Benton, D., Williams, C., & Brown, A. (2007). Impact of consuming a milk drink containing a probiotic on mood and cognition. European Journal of Clinical Nutrition, 61(3), 355-361.
    Bernhard, J., Hurny, C., Maibach, R., Herrmann, R., & Laffer, U. (1999). Quality of life as subjective experience: Reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology, 10(7), 775-782.
    Black, F.T., Andersen, P.L., Orskov, J., Gaarslev, K., & Laulund, S. (1989). Prophylactic efficacy of lactobacilli on traveler's diarrhea. Travel Medicine, 7, 333-335.
    Cassileth, B.R., Lusk, E.J., Guerry, D., Blake, A.D., Walsh, W.P., Kascius, L., et al. (1991). Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. New England Journal of Medicine, 324(17), 1180-1185.
    Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570-579.
    Deng, G.E., Cassileth, B.R., Cohen, L., Gubili, J., Johnstone, P.A., Kumar, N., et al. (2007). Integrative oncology practice guidelines. Journal of the Society for Integrative Oncology, 5(2), 65-84.
    deVrese, M., & Marteau, P.R. (2007). Probiotics and prebiotics: Effects on diarrhea. Journal of Nutrition, 137(3, Suppl. 2), 803S-811S.
    Ernst, E., & Cassileth, B.R. (1998). The prevalence of complementary/alternative medicine in cancer: A systematic review. Cancer, 83(4), 777-782.
    Eser, S.E. (2007). Cancer incidence in Turkey. In M. Tuncer (Ed.), Cancer control in Turkey (pp. 17-44). Ankara, Turkey: Ministry of Health.
    Henderson, J.W., & Donatelle, R.J. (2004). Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Alternative Therapies in Health and Medicine, 10(1), 52-57.
    Hessig, R.E., Arcand, L.L., & Frost, M.H. (2004). The effects of an educational intervention on oncology nurses' attitude, perceived knowledge, and self-reported application of complementary therapies. Oncology Nursing Forum, 31(1), 71-78.
    Jordan, M.L., & Delunas, L.R. (2001). Quality of life and pattern of nontraditional therapy use by patients with cancer. Oncology Nursing Forum, 28(7), 1107-1113.
    Kim, D.J., Kim, T.I., Suh, J.H., Cho, Y.S., Shin, S.K., Kang, J.K., et al. (2003). Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer. Yonsei Medical Journal, 44(4), 665-675.
    Kozachik, S.L., Wyatt, G., Given, C.W., & Given, B.A. (2006). Patterns of use of complementary therapies among cancer patients and their family caregivers. Cancer Nursing, 29(2), 84-94.
    Lis, C.G., Cambron, J.A., Grutsch, J.F., Granick, J., & Gupta, D. (2006). Self-reported quality of life in users and nonusers of dietary supplements in cancer. Supportive Care in Cancer, 14(2), 193-199.
    Otles, S., & Cagandi, O. (2003). Kefir: A probiotic dairy composition, nutritional and therapeutic aspects. Pakistan Journal of Nutrition, 2(2), 54-59.
    Paltiel, O., Avitzour, M., Peretz, T., Cherny, N., Kaduri, L., Pfeffer, R.M., et al. (2001). Determinants of the use of complementary therapies by patients with cancer. Journal of Clinical Oncology, 19(9), 2439-2448.
    Parvez, S., Malik, K.A., Ah Kang, S., & Kim, H.Y. (2006). Probiotics and their fermented food products are beneficial for health. Journal of Applied Microbiology, 100(6), 1171-1185.
    Patterson, R.E., Neuhouser, M.L., Hedderson, M.M., Schwartz, S.M., Standish, L.J., Bowen, D.J., et al. (2002). Types of alternative medicine used by patients with breast, colon, or prostate cancer: Predictors, motives, and costs. Journal of Alternative and Complementary Medicine, 8(4), 477-485.
    Portenoy, R.K., Thaler, H.T., Kornblith, A.B., Lepore, J.M., Friedlander-Klar, H., Kiyasu, E., et al. (1994). The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics, and distress. European Journal of Cancer, 30A(9), 1326-1336.
    Richardson, M.A., Sanders, T., Palmer, J.L., Greisinger, A., & Singletary, S.E. (2000). Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. Journal of Clinical Oncology, 18(13), 2505-2514.
    Roberfroid, M.B. (2000). Prebiotics and probiotics: Are they functional foods? American Journal of Clinical Nutrition, 71(6, Suppl.), 1682S-1690S.
    Rolfe, R.D. (2000). The role of probiotic cultures in the control of gastro-intestinal health. Journal of Nutrition, 130(2S, Suppl.), 396S-402S.
    Tas, F., Ustuner, Z., Can, G., Eralp, Y., Camlica, H., Basaran, M., et al. (2005). The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncologica, 44(2), 161-167.
    Zaniboni, A., Labianca, R., Marsoni, S., Torri, V., Mosconi, P., Grilli, R., et al. (1998). GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma—Long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon. Cancer, 82(11), 2135-2144.